These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16041163)

  • 1. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
    Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
    Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
    Kondo I; Mizushige K; Nozaki S; Iwado Y; Masugata H; Kohno M; Matsuo H
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):459-65. PubMed ID: 11855665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
    Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
    Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
    Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
    Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
    Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
    Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
    Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
    J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
    Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
    J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
    Hamada M; Shigematsu Y; Hara Y; Suzuki M; Ohtsuka T; Hiasa G; Ogimoto A; Saeki H; Suzuki J; Hiwada K
    Jpn Circ J; 2001 Jun; 65(6):531-8. PubMed ID: 11407736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitral regurgitation disappearance after cibenzoline treatment in a patient with hypertrophic obstructive cardiomyopathy.
    Inada K; Komukai K; Mori C; Nagasawa H; Shibata T; Mochizuki S
    Intern Med; 2004 Jan; 43(1):55-8. PubMed ID: 14964580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
    Kondo I; Mizushige K; Nozaki S; Hirao K; Iwado Y; Ohmori K; Matsuo H
    Clin Cardiol; 2000 Sep; 23(9):689-96. PubMed ID: 11016020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.
    Ishikawa T; Iwashima S; Ohzeki T
    Pediatr Cardiol; 2010 Jul; 31(5):707-10. PubMed ID: 20140606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intraventricular flow dynamics in hypertrophic cardiomyopathy with midventricular obstruction investigated by Doppler echocardiography].
    Nakamura T; Kitamura H; Furukawa K; Matsubara K; Katahira T; Okamuro S; Tsuji Y; Takahashi T; Kunishige H; Katsume H
    J Cardiol; 1989 Jun; 19(2):455-71. PubMed ID: 2636627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An early systolic sound associated with midventricular obstruction in a patient with hypertrophic cardiomyopathy.
    Ohtsuka T; Hamada M; Hara Y; Kuwahara T; Kodama K; Shigematsu Y; Iwata T; Hiwada K
    Jpn Circ J; 1998 May; 62(5):385-8. PubMed ID: 9626909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient bradycardia induced by carotid sinus pressure increases outflow obstruction in hypertrophic obstructive cardiomyopathy but not in valvular aortic stenosis.
    Klein HO; Keren G; Bakst A; Laniado S; Lang R; Kaplinsky E; Di Segni E
    Chest; 1998 Aug; 114(2):469-76. PubMed ID: 9726732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cibenzoline attenuates coronary systolic reversal flow in a patient with hypertrophic obstructive cardiomyopathy: a case report.
    Saihara K; Hamasaki S; Otsuji Y; Yoshitama T; Ishida S; Kataoka T; Okui H; Tei C
    J Cardiol; 2006 Oct; 48(4):209-13. PubMed ID: 17066624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue Doppler imaging in hypertrophic cardiomyopathy: impact of intraventricular obstruction on longitudinal left ventricular function.
    Cardim N; Torres D; Morais H; Cândido A; Duarte R; Longo S; Ferreira T; Pereira A; Gouveia A; Reis RP; Correia JM
    Rev Port Cardiol; 2002 Mar; 21(3):271-97. PubMed ID: 12017801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic agent cibenzoline attenuates latent obstruction in the left ventricular outflow tract of hypertrophic cardiomyopathy.
    Nomura T; Kojima A; Urakabe Y; Enomoto-Uemura S; Nishikawa S; Keira N; Matsubara H; Tatsumi T
    Int J Cardiol; 2011 May; 148(3):359-61. PubMed ID: 20888654
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic usefulness of carotid pulse tracing in patients with hypertrophic obstructive cardiomyopathy due to midventricular obstruction: a comparison with idiopathic hypertrophic subaortic stenosis.
    Hamada M; Shigematsu Y; Ohshima K; Suzuki J; Ogimoto A; Ohtsuka T; Hara Y
    Chest; 2003 Oct; 124(4):1275-83. PubMed ID: 14555556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.